Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00109135 |
The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.
Condition | Intervention | Phase |
---|---|---|
Smoking |
Drug: taranabant |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation |
Enrollment: | 300 |
Study Start Date: | April 2004 |
Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2005_012, MK0364-007 |
Study First Received: | April 22, 2005 |
Last Updated: | May 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00109135 |
Health Authority: | United States: Food and Drug Administration |
Smoking |
Habits |